CN113350356B - 2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects - Google Patents
2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects Download PDFInfo
- Publication number
- CN113350356B CN113350356B CN202110579672.2A CN202110579672A CN113350356B CN 113350356 B CN113350356 B CN 113350356B CN 202110579672 A CN202110579672 A CN 202110579672A CN 113350356 B CN113350356 B CN 113350356B
- Authority
- CN
- China
- Prior art keywords
- cells
- resistant
- drug
- compound
- mcf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to a 2,4, 7-trisubstituted pyrimidoindole structure compound, which can inhibit the growth of various drug-resistant tumor cells, and particularly can effectively inhibit the proliferation of adriamycin-resistant breast cancer, cisplatin-resistant lung cancer and cisplatin-resistant liver cancer cells. In addition, the compound can inhibit the clone formation of drug-resistant tumor cells at a very low concentration and inhibit the in-vitro excretion function of P-glycoprotein and ABCG2 transporters. The invention also relates to a preparation method of the compound and application of the compound in tumor treatment or adjuvant therapy.
Description
Technical Field
The invention relates to a 2,4, 7-trisubstituted pyrimidoindole compound, a preparation method thereof and application thereof in tumor drug resistance treatment.
Background
In recent years, tumors have become one of the leading causes of human death. With the continuous discovery of antineoplastic drugs such as cisplatin, adriamycin, paclitaxel and the like, chemotherapy has become one of the main methods for treating malignant tumors. However, after some time of chemotherapy with cisplatin, doxorubicin and paclitaxel, the serious problem of acquired tumor resistance is usually inevitable, and the tumor resistance becomes a main cause of failure of clinical treatment and poor prognosis.
The compound is a 2,4, 7-trisubstituted pyrimidoindole structure, can inhibit the growth of adriamycin, cis-platinum and taxol-resistant breast cancer cells, lung cancer cells and liver cancer cells, and particularly can efficiently kill the adriamycin-resistant breast cancer cells. In addition, the compound of the invention can inhibit the cloning formation of the adriamycin-resistant breast cancer cells at a very low concentration, which has important clinical significance for inhibiting the growth of cancers. The invention also finds that the compound can inhibit the discharge function of P glycoprotein of tumor cells and a transporter, thereby inhibiting the discharge of the tumor cells to the medicine and improving the intracellular concentration of the chemotherapeutic medicine. Therefore, the compounds have wide application prospect in tumor treatment or adjuvant therapy.
Numerous studies have shown that tumor cells (e.g., breast, pancreatic, prostate) highly express the sigma-2 receptor (more than 10-fold higher than surrounding normal tissues) during the course of canceration, and therefore, compounds with high affinity for the sigma-2 receptor are able to selectively bind to tumor cells that highly express the sigma-2 receptor. Currently, breast cancer diagnosis mainly depends on radiography (such as CT, with radiation side effect), observation, biopsy (requiring invasive sampling), and other means. The main disadvantages of these methods are their high cost, low accuracy (high false positives, high false negatives) and great physical damage.
The invention relates to a series of compounds with fluorescent structures, high affinity activity and selectivity on sigma-2 receptors, which can be effectively and selectively bound to the sigma-2 receptors and can be applied to diagnosis of tumors by utilizing the characteristic of fluorescence emission. The compounds can antagonize the binding of A beta in nerve cells, prevent the signal transduction and cytotoxicity caused by the A beta, and have the functions of diagnosis, treatment or improvement of AD.
Disclosure of Invention
The invention mainly relates to a 2,4, 7-trisubstituted pyrimidoindole compound, a preparation method thereof and application thereof in tumor drug resistance treatment.
The invention also provides processes and intermediates useful for preparing the compounds of the invention.
The invention also provides compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the invention or its isomers, prodrugs, pharmaceutically acceptable salts.
The compounds of the invention are useful in the treatment of drug resistant tumors.
The compound can be used for preparing a medicinal composition for treating drug-resistant tumors.
The compounds of the invention are useful for killing drug-resistant tumor cells.
The compounds of the invention are useful for inhibiting the clonogenic formation of drug-resistant tumor cells.
The compounds of the invention are useful for inhibiting the efflux function of P glycoprotein.
The compounds of the invention are useful for inhibiting ABCG2 transporter excretion function in vitro.
The compounds of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more other drugs.
Drawings
FIG. 1 Effect of compound XH003 on the clonogenic formation of MCF-7/ADR cells and their parental cells
Detailed Description
A first aspect of the present disclosure relates to the use of compound XH003, or a pharmaceutically acceptable salt, or ester, or prodrug thereof, in the manufacture of a medicament for the treatment of a drug-resistant tumour:
in one embodiment, the medicament comprises compound XH003 or an isomer, prodrug, pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable adjuvants or excipients.
In one embodiment, the drug resistant tumor is selected from one or more of doxorubicin-resistant breast cancer, cisplatin-resistant lung cancer, and cisplatin-resistant liver cancer cells.
In one exemplary embodiment, the drug resistant tumor is selected from an doxorubicin-resistant breast cancer.
In one embodiment, the treatment-resistant tumor is formed by inhibiting the cloning of tumor cells.
In one embodiment, the treatment-resistant tumor is by inhibiting P glycoprotein efflux function.
In one embodiment, the treatment-resistant tumor is by inhibiting ABCG2 transporter excretion function in vitro.
In one embodiment, the treatment-resistant tumor is by simultaneously inhibiting tumor cell cloning, inhibiting P glycoprotein efflux, and inhibiting ABCG2 transporter efflux function in vitro.
The embodiment is as follows:
example 1: synthesis of 2-benzyl-4- (6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinolin-2-ethylamino) -7- (2-methyltetrazol-5-yl) pyrimidi-ne [4,5] oxindole (XH 003)
1.1 Synthesis of 5- (3-nitrophenyl) tetrazole (B001)
Taking 30.0g (202.69 mmol) of m-nitrobenzonitrile, 14.5g (222.96 mmol) of sodium azide and 45.7g (202.69 mol) of zinc bromide in a 1000ml flask, adding 500ml of water, carrying out reflux reaction at 100 ℃ for 24 hours, then cooling to room temperature, pouring a reaction liquid into 500ml of water, adding 100ml of 3N hydrochloric acid, extracting with ethyl acetate (3 x 200 ml), collecting an organic phase, carrying out rotary drying on the ethyl acetate under reduced pressure to obtain a white solid, adding 800ml of 0.25mol/L NaOH, stirring, dissolving the solid, then precipitating white flocculent zinc hydroxide again, carrying out suction filtration, adjusting the pH of a filtrate to =5 by using 3.0mol/L hydrochloric acid, and precipitating a large amount of white solid, 34.8g of a dried white product, wherein the yield is 90%.
The structure of the product is confirmed: 1 H NMR(DMSO-d6,ppm)δ8.85-8.86(t,1H),8.48-8.51(dt,1H)，8.43- 8.46(dq,1H),7.91-7.95(t,1H)。
1.2 Synthesis of 2-methyl-5- (3-nitrophenyl) tetrazole (B002)
33.0g (172.64 mmol) of intermediate B is taken to be dissolved in 150ml DMF, 28.63g (207.17 mmol) of anhydrous potassium carbonate and 29.41g (207, 17 mmol) of methyl iodide are added to react for 1h at the temperature of 90 ℃, the reaction solution is cooled to room temperature and is dark yellow, the reaction solution is slowly dropped into 1L of water, a large amount of white solid is separated out, and the white solid is obtained after suction filtration and drying. Recrystallization from ethyl acetate and petroleum ether gave 26g of product, 72.2% yield.
And (3) confirming the structure of a product: 1 H NMR(DMSO-d6,ppm)δ8.66-8.67(t,1H),8.40-8.42(dt,1H),8.33-8.35 (dt,1H),7.81-7.85(t,1H),4.46(s,3H)。
1.3 Synthesis of N-hydroxy-N-acetyl-4- (2-methyltetrazol-5-yl) aniline (B003)
Taking 30g (146.22 mmol) of intermediate B002, dissolving in 350ml tetrahydrofuran at room temperature, adding 10.0g of NI powder, cooling to 0 ℃ in an ice bath, dropwise adding 7.3g (143, 49 mmol) of hydrazine hydrate slowly in batches, stirring for 30min at 0 ℃, slowly heating to room temperature to continue reacting for 24h, wherein the solution becomes light yellow, monitoring by TLC (thin layer chromatography) that the raw material disappears, cooling to 0 ℃, adding 54g of 4 equivalent sodium bicarbonate with gas generation, stirring for 30mim, dropwise adding 13.77g (175.46 mmol) of acetyl chloride at 0 ℃, slowly heating to room temperature to react for 2h, suction filtering, washing a filter cake with tetrahydrofuran (3 x 50 ml), collecting a filtrate, and carrying out decompression and spin drying on the tetrahydrofuran to obtain a yellow solid. The solid was recrystallized from ethyl acetate to give 28g of the product in 84% yield.
The structure of the product is confirmed: 1 H NMR(DMSO-d6,ppm)δ10.83(s,1H),8.43(s,1H),7.82-7.84(d,2H), 7.54-7.58(t,1H),4.45(s,3H),2.28(s,3H)。
1.4 Synthesis of 2-amino-6- (2-methyltetrazole-5-) indole-3-formamide (B004)
Dissolving 26.0g (111.48 mmol) of the intermediate B003 in 500ml of chloroform, dissolving part of solid, adding 7.4g (111.48 mmol) of malononitrile, cooling to 0 ℃, stirring for 30 mm, slowly dropping 11.28g (111.48 mmol) of triethylamine, stirring for 30min after dropping, slowly heating to room temperature for reaction for 1h, separating out a large amount of solid, performing suction filtration, washing a filter cake with (3X 50 ml) of chloroform, placing the filter cake in a 500ml flask, adding 11.28g (111.48 mmol) of triethylamine, 200ml of methanol, performing reflux reaction for 10h, clarifying a reaction liquid, separating out a large amount of off-white solid, concentrating the filtrate under reduced pressure, and performing suction filtration to obtain 16g of off-white solid, wherein the yield is 58%.
The structure of the product is confirmed: 1 H NMR(DMSO-d6,ppm)δ10.80(s,1H),7.82(s,1H),7.64-7.68(q,2H), 7.03(s,2H),6.60(s,2H),4.39(s,3H)。
1.5 Synthesis of 2-phenylacetylamino-6- (2-methyltetrazole-5-) indole-3-formamide (B005)
14.6g (56.34 mmol) of B004 is dissolved in 200ml of DMF, 17.1g (169.03 mmol) of triethylamine and 17.42g (112.69 mmol) of phenylacetyl chloride are added to react at 37 ℃ for 24h, the reaction solution is slowly dropped into 500ml of water, a large amount of yellow solid is precipitated, and the yellow solid is filtered off by suction and dried. The solid was placed in a 500ml flask, 200ml ethyl acetate was added, reflux was taken for 6h and suction filtered to give 15.0g of off-white product in 70.9% yield.
The structure of the product is confirmed: 1 H NMR(DMSO-d6,ppm)δ12.23(s,1H),11.76(s,1H),8.29(s,1H),7.96- 8.00(m,1H),7.79-7.81(m,1H),7.26-7.40(m,7H),4.41(s,3H),3.91(s,2H)。
1.6 Synthesis of 2-benzyl-7- (2-methyltetrazol-5-yl) -3H-4-oxy-pyrimido [4,5] indole (B006)
Dissolving 16.3g (43.4 mmol) of intermediate B in 500ml of isopropanol, adding 29.2g (260.4 mmol) of potassium tert-butoxide, refluxing at 90 ℃ for 12h, decompressing and concentrating the reaction solution after the raw material point disappears, adding 300ml of water, adjusting the pH with 6mol/L hydrochloric acid solution to be =6, and filtering to obtain an off-white solid. The solid was placed in a 1L flask, 500ml methanol was added, refluxing was carried out for 8h, suction filtration was carried out repeatedly for 3 times to obtain 11.6g of a white product with a yield of 74.8%.
And (3) confirming the structure of a product: 1 H NMR(DMSO-d6,ppm)δ12.48(b,1H),12.40(b,1H),8.07-8.20(m, 3H),7.91-7.97(m,1H),7.26-7.41(m,4H),4.43(s,3H),4.04(s,2H)。
1.7 Synthesis of 2-benzyl-4-chloro-7- (2-methyltetrazol-5-yl) pyrimidine [4,5] oxindole (B007)
6.3g (16.76 mmol) of intermediate B006 was placed in a 250ml flask, phosphorus oxychloride was added to 100ml, the mixture was refluxed at 110 ℃ for 12 hours, the reaction mixture was concentrated under reduced pressure to about 20ml, slowly dropped into 500ml of ice water, stirred to precipitate a yellow solid, the pH was adjusted to about 8 with 10% NaOH solution, suction filtered, and dried to obtain 6.1g of a yellow product with a yield of 92%.
The structure of the product is confirmed: 1 H NMR(DMSO-d6,ppm)δ12.90(s,1H),8.32-8.35(d,1H),8.19(s,1H), 8.04-8.07(dd,1H),7.22-7.38(m,5H),4.46(s,3H),4.30(s,2H)。
1.8 Synthesis of 2- (6, 7-methoxy-3, 4-dihydroisoquinoline) -ethylenediamine
10.0g (48.81 mmol) of bromoethylamine hydrobromide and 7.42g (73.22 mmol) of triethylamine are taken to be dissolved in 50ml of ethanol, ice bath is carried out to 0 ℃, 12.85g (58.57 mmol) of Boc-anhydride is dripped, after the dripping is finished, the temperature is slowly raised to room temperature for reaction for 15h, after the reaction is finished, ethanol is dried under reduced pressure, 50ml of water is added, ethyl acetate (3X 100 ml) is used for extraction, an organic phase is collected, anhydrous sodium sulfate is dried, ethyl acetate is dried under reduced pressure, 10.0g of Boc-bromoethylamine is obtained as a light yellow oily product, and the yield is 91.4%.
Dissolving 2.0g (8.8 mmol) of 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline hydrochloride in 25ml of dichloromethane, adding 2.64g (26.12 mmol) of triethylamine and 2.34g (10.45 mmol) of Boc-bromoethylamine, stirring at room temperature overnight, pouring 50ml of water into the reaction solution after the reaction is finished, extracting the water layer with 3 × 50ml of dichloromethane, collecting the organic phase, drying with anhydrous sodium sulfate, adding 4.0g of silica gel powder, purifying the product by silica gel column chromatography (eluent: ethyl acetate: petroleum ether = 1) to obtain 2.4g of oily product, adding 20ml of dichloromethane, dropping 1ml of trifluoroacetic acid, stirring at room temperature for 6h, spin-drying dichloromethane under reduced pressure, adding 20ml of water, adjusting pH =10 with 10% sodium hydroxide solution, extracting with dichloromethane (3 × 50 ml), collecting the organic phase, drying with anhydrous sodium sulfate, and spin-drying dichloromethane under reduced pressure to obtain 1.6g of light yellow oily product with a yield of 95%. Directly used for the next reaction.
1.9 Synthesis of the target product XH003
Taking 0.4g (1.07 mmol) of intermediate B007, dissolving in 10ml DMSO, adding 0.3g (2.14 mmol) of anhydrous potassium carbonate and 0.5g (2.14 mmol) of 2- (6, 7-methoxy-3, 4-dihydroisoquinoline) -ethylenediamine, reacting for 8h at 90 ℃, dropping the reaction liquid into ice water after the reaction is finished, precipitating a light yellow solid, carrying out suction filtration, drying, recrystallizing the light yellow solid ethyl acetate to obtain 0.18g of XH003 with the yield of 29%.
And (3) confirming the structure of a product: 1 H NMR(DMSO-d6,ppm)δ12.03(s,1H),8.35-8.37(d,J＝8.2,1H),8.08 (s,1H),7.88-7.90(d,J＝8.2,1H),7.39-7.41(d,J＝7.2,2H),7.27-7.31(d,J＝7.4,3H),7.18-7.22(t, J＝7.3,1H),6.63-6.66(m,2H),4.43(s,3H),4.08(s,2H),3.80-3.85(m,2H),3.69-3.70(6H,2OMe), 3.58(s,2H),2.71-2.76(m,6H)；13C NMR(DMSO-d6,ppm)δ166.61,165.33,157.48,157.20, 147.60,147.34,139.86,136.83,129.62(2C),128.57(2C),127.11,126.47,126.39,122.82,121.84, 121.75,118.51,112.26,110.41,109.14,93.97,57.27,55.95,55.91,55.72,51.12,46.29,38.33, 28.70；LC/MS-m/z:576.4[M+1]+(exact mass:575.3)。
example 2: determination of toxic effect and drug-resistant fold of compound XH003 on MCF-7/ADR, A549/DDP, hepG2/DDP and parent cells thereof
Digesting with pancreatin for 2min when the cells in good growth state have grown to 80%, terminating the digestion with a medium containing 10% FBS to prepare a uniform single cell suspension, inoculating to a 96-well plate at a cell density of 5000 cells/well, and culturing in a cell incubator; 24h after inoculation, cells were grouped as follows: DMEM complete medium treated group (placebo), different XH003 drug concentration groups (1.25, 2.5, 5, 10, 20, 40) and doxorubicin, cisplatin and paclitaxel positive drugs; after the administration treatment is carried out for 24h, 48h and 72h respectively, the cell proliferation condition is detected by using a CCK-8 method, the old culture medium is discarded, 100 mu l of CCK-8 working solution is added, the culture is continued for 1.5h in an incubator, and the absorbance of each hole is measured by using an enzyme-labeling instrument at the wavelength of 450 nm.
Survival = [ (experimental absorbance-blank well absorbance)/(control absorbance-blank well absorbance) ].: 100%, fold resistance = resistant cell IC 50/IC 50 of parental cell
The CCK-8 method detects the toxicity of XH003 to the cell proliferation of three drug-resistant cells MCF-7/ADR, A549/DDP, hepG2/DDP and parent cells thereof for 24h, 48h and 72h, and uses Adriamycin (ADR), cisplatin (DDP) and paclitaxel as a positive control group. Results show that compared with positive drugs of adriamycin and cisplatin, XH003 has obvious inhibition effect on the proliferation of three multidrug resistant cells MCF-7/ADR, A549/DDP and HepG2/DDP, and the effect is equivalent to that of parent cells and is concentration-dependent; the positive medicines adriamycin and cisplatin have obviously weakened proliferation inhibition effect on drug-resistant cells MCF-7/ADR, A549/DDP and HepG2/DDP (see tables 1-6).
And calculating the IC50 of the drug-resistant cells with XH003 and positive drug effects and parent cells at 48h, and comparing the drug-resistant times of the drug-resistant cells with the parent cells. The results showed that XH003 exhibited good antitumor multi-drug resistance activity against three multi-drug resistant cells (1.41, 1.69, 2.04 μ M), and against doxorubicin (44.57, 0.95, 371.61 μ M), cisplatin (5.55, 6.29, 4.54 μ M), and paclitaxel (25.13, 54.86, 37.92 μ M, respectively) (table 7).
TABLE 1 Effect of XH003 on survival of MCF-7/ADR cells
* P <0.05, P <0.01 in comparison with the blank group
TABLE 2 Effect of XH003 on survival of MCF-7 cells
* P <0.01 in comparison to blank group
TABLE 3 Effect of XH003 on the survival of A549/DDP cells
* P <0.05, P <0.01 in comparison with the blank group
TABLE 4 Effect of XH003 on A549 cell survival
* P <0.01 in comparison to blank group
TABLE 5 Effect of XH003 on HepG2/DDP cell survival
* P <0.01 in comparison to blank group
TABLE 6 Effect of XH003 on HepG2 cell survival
* P <0.01 in comparison to blank group
TABLE 7 toxic Effect (IC 50) of XH003 on various drug resistant cells MCF-7/ADR, A549/DDP, hepG2/DDP and their parental cells, and fold drug resistance
| XH003 | Adriamycin | Cis-platinum | Paclitaxel | |
| MCF-7/ADR | 5.35±0.42 | 27.19±0.28 | 45.83±1.58 | 18.85±0.45 |
| MCF-7 | 3.79±0.13 | 0.61±0.019 | 8.26±0.40 | 0.75±0.026 |
| Multiple of drug Resistance (RF) | 1.41 | 44.57 | 5.55 | 25.13 |
| A549/DDP | 7.74±0.32 | 0.20±0.06 | 72.67±2.93 | 23.04±0.92 |
| A549 | 4.59±0.35 | 0.21±0.01 | 11.55±0.36 | 0.42±0.05 |
| Multiple of drug Resistance (RF) | 1.69 | 0.95 | 6.29 | 54.86 |
| HepG2/DDP | 8.29±0.04 | 48.31±3.10 | 52.90±0.63 | 20.86±0.43 |
| HepG2 | 4.07±0.25 | 0.13±0.12 | 11.65±0.60 | 0.55±0.09 |
| Multiple of drug Resistance (RF) | 2.04 | 371.61 | 4.54 | 37.92 |
Example 3: the effect of the compound XH003 on the cloning formation of MCF-7/ADR cells and parent cells thereof MCF-7/ADR cells with good growth are taken, after digestion counting, the MCF-7 and MCF-7/ADR cells are seeded in a six-well plate at 5000/well for 24h, and after the cells are attached to the wall, the MCF-7 and MCF-7/ADR cells are divided into the following groups: complete medium group (control group), XH003 (0.3125, 0.625, 1.25, 2.5, 5. Mu.M), drug effect 24h later, replaced complete medium culture for 10 days, every other day dosing. After culturing for 10 days, terminating the culture, removing the culture solution, washing the cells for 2 times by PBS (phosphate buffer solution), fixing the cells by 4% paraformaldehyde for 30min, adding 1% crystal violet for dyeing for 15min, slowly washing the dyeing solution by distilled water, drying, and photographing under an inverted microscope to observe and count the cloned colony cells with more than 50 cells. Colony formation rate = (number of clones/number of seeded cells) × 100.
The results showed that XH003 (1.25, 2.5, 5. Mu.M) significantly inhibited the clonogenic formation of MCF-7/ADR and MCF-7 cells (P < 0.05) compared to the blank control, and that at the same concentration, XH003 inhibited the clonogenic formation of MCF-7/ADR as effectively as MCF-7 (see FIG. 1).
Example 4: effect of compound XH003 on accumulation of rhodamine 123 (Rh 123) in MCF-7/ADR cells and their parent cells
To investigate the mechanism of XH003 antitumor resistance, the effect of XH003 on the transport function of P glycoprotein was explored by an experiment in which Rh123 was accumulated in cells. Taking well-grown cells, digesting, centrifuging, resuspending to prepare a cell suspension, inoculating the cell suspension on a 6-well plate at the cell density of 2X 105, and culturing for 24 hours in a cell incubator at 37 ℃; after the cells are attached, the cells are grouped as follows: (1) drug-free placebo; (2) different concentrations of XH003 (1.25, 2.5, 5, 10. Mu.M); and (3) the verapamil group as the positive drug is 10 mu M. Firstly, discarding an old culture medium, respectively adding different medicines, and continuously culturing for 2 hours in a cell incubator; then, the old culture medium is discarded, 1mL of PBS is added to wash the cells for 2 times, 5 mu g/mL of Rh123 is added to each group of cells, and the cells are incubated for 30min; after incubation, adding 1ml of PBS to clean cells for 2 times, adding pancreatin to digest and centrifuge, discarding old culture medium, adding 2ml of PBS to fully resuspend cells, rotating at 2000rpm, and centrifuging for 10min; the supernatant was then discarded, 500. Mu.l of PBS was added to resuspend the cells and transferred to a flow tube, and the fluorescence intensity was measured by flow cytometry.
The results show that the concentration of Rh123 in MCF-7/ADR cells and MCF-7 of parent cells thereof is obviously improved by XH003 at concentrations of 2.5, 5 and 10 mu M (P < 0.05) in a concentration-dependent manner compared with a blank control group, and the intracellular accumulation effect of 2.5 mu M XH003 in MCF-7/ADR cells is equivalent to that of a P-gp transporter inhibitor verapamil 10 mu M, which indicates that XH003 can inhibit the transport function of P glycoprotein, thereby increasing the intracellular concentration of chemotherapeutic drugs (see Table 8).
TABLE 8 Effect of XH003 on Rh123 accumulation in MCF-7/ADR cells and their parental cells
* P <0.05, P <0.01 in comparison to blank group
Example 5: effect of Compound XH003 on Rh123 efflux from MCF-7/ADR cells
To further confirm that intracellular accumulation of Rh123 was related to inhibition of P glycoprotein-mediated drug efflux by XH003, we performed Rh123 efflux experiments to monitor changes in intracellular concentrations of Rh123 at MCF-7/ADR within 30, 60, 90, 120min for XH 003. After cell digestion and centrifugation, the suspension was resuspended in a cell suspension, seeded at a cell density of 2X 105 onto a 6-well plate, cultured in a cell incubator at 37 ℃ for 24 hours, and the cells were grouped into (1) a drug-free blank control group, (2) XH003 (1.25, 2.5. Mu.M) at different concentrations, and (3) verapamil group, a positive drug, at 10. Mu.M, respectively.
After the cells adhere to the wall, 5 mu g/mL of Rh123 was added and the culture was continued for 2h in the incubator. Then, the cells were washed 2 times with 1ml of PBS, and further incubated for 0, 30, 60, 90, and 120min by adding drugs of different concentrations. After the incubation is finished, adding 1ml of PBS to clean the cells for 2 times, adding pancreatin to digest and centrifuge, adding 2ml of PBS to resuspend the cells, rotating at 2000rpm, and centrifuging for 10min; the supernatant was discarded, 500. Mu.l of PBS was added to resuspend the cells and transferred to a flow tube, and the fluorescence intensity was measured by flow cytometry.
The results show that after removal of Rh123, cell concentrations of Rh123 at 30min were about 76%, 92%, 75% for XH003 (1.25, 2.5 μ M) and verapamil (10 μ M), respectively, while the blank was 45%; at 60min, the cell concentrations of XH003 (1.25, 2.5. Mu.M), verapamil (10. Mu.M) and Rh123 in the blank were about 74%, 92%, 34%, 22%, respectively; at 90min, the cell concentrations of XH003 (1.25, 2.5. Mu.M), verapamil (10. Mu.M) and Rh123 of the blank were about 69%, 96%, 35%, 20%, respectively; at 120min, the cell concentrations of XH003 (1.25, 2.5. Mu.M), verapamil (10. Mu.M) and Rh123 in the blank control were about 69%, 90%, 31% and 20%, respectively, and the inhibitory effect of XH003 (1.25, 2.5. Mu.M) was significantly better than that of verapamil (10. Mu.M). The results show that XH003 can inhibit the efflux function of P glycoprotein transporter, reduce the efflux of Rh123 in MCF-7/ADR cells and is concentration-dependent (see Table 9).
TABLE 9 Effect of XH003 on Rh123 efflux from MCF-7/ADR cells
* P <0.01 in comparison to blank group
Example 6: effect of Compound XH003 on mitoxantrone accumulation in MCF-7/ADR cells and their parent cells
To explore the effect of XH003 on the transport function of the ABCG2 transporter, the effect of XH003 on mitoxantrone accumulation in cells was observed with MCF-7/ADR and its parental cell MCF-7. Taking well-grown cells, digesting, centrifuging, resuspending to prepare a cell suspension, inoculating the cell suspension on a 6-well plate at the cell density of 2X 105, and culturing for 24 hours in a cell incubator at 37 ℃; after the cells adhere to the wall, the cells are grouped as follows: (1) drug-free placebo; (2) different concentrations of XH003 (1.25, 2.5, 5, 10. Mu.M); (3) Positive drug KO 143. Mu.M. Firstly, discarding an old culture medium, respectively adding different medicines, and continuously culturing for 2 hours in a cell incubator; then, discarding the old culture medium, adding 1ml PBS to clean the cells for 2 times, adding 5 mu mol/L mitoxantrone into each group of cells, and incubating for 30min; after the incubation is finished, adding 1ml of PBS to wash the cells for 2 times, digesting and centrifuging the cells by using pancreatin, then adding 2ml of PBS to fully suspend the cells, and centrifuging at 2000rpm for 10min; the supernatant was then discarded, 500. Mu.l of PBS was added to resuspend the cells and transferred to a flow tube, and the fluorescence intensity was measured by flow cytometry.
The results showed that XH003 at a concentration of 2.5, 5, 10. Mu.M and the ABCG2 transporter inhibitor KO143 (10. Mu.M) significantly increased the concentration of mitoxantrone accumulated in MCF-7/ADR and its parent cell MCF-7 cells (P < 0.05), and that XH003 had an effect on mitoxantrone accumulation in MCF-7 cells equivalent to KO143, indicating that XH003 had a certain inhibitory effect on the transport function of the ABCG2 transporter (see Table 10)
TABLE 10 Effect of XH003 on mitoxantrone accumulation in MCF-7/ADR cells
* P <0.05, P <0.01 in comparison to blank group
Example 7: effect of Compound XH003 on mitoxantrone efflux in MCF-7/ADR cells
To further determine that intracellular accumulation of mitoxantrone was associated with XH003 inhibition of ABCG2 mediated drug efflux, cell digestion was centrifuged, resuspended as a cell suspension, seeded at a cell density of 2 × 105 in 6-well plates, incubated at 37 ℃ for 24h in a cell incubator, and the cells were grouped into (1) drug-free control, (2) different concentrations of a011 (1.25, 2.5, 5, 10 μ M), (3) positive drug KO143 group 10 μ M, respectively. After the cells are attached to the wall, 5 mu mol/L mitoxantrone is added and the culture is continued for 2h in the incubator. Then, the cells were washed 2 times with 1ml PBS, and further incubated for 0, 30, 60, 90, and 120min by adding different concentrations of drugs. After the incubation is finished, adding 1ml of PBS to clean the cells for 2 times, adding pancreatin to digest and centrifuge, adding 2ml of PBS to resuspend the cells, rotating at 2000rpm, and centrifuging for 10min; the supernatant was discarded, 500. Mu.l of PBS was added to resuspend the cells and transferred to a flow tube, and the fluorescence intensity was measured by flow cytometry.
As a result, as shown in Table 11 below, XH003 (1.25, 2.5, 5, 10. Mu.M) was found to significantly increase the intracellular mitoxantrone content after removing mitoxantrone, and to have an effect of suppressing efflux superior to that of KO143 (10. Mu.M), compared to the control group, and the results showed that XH003 could increase the intracellular mitoxantrone content by suppressing the efflux function of ABCG2 (see Table 11).
TABLE 11 Effect of XH003 on mitoxantrone efflux in MCF-7/ADR cells
* P <0.05, P <0.01 compared to blank group.
Claims (3)
1. The application of a compound XH003 or a pharmaceutically acceptable salt thereof in preparing a medicament for treating drug-resistant tumors, wherein the drug-resistant tumors are selected from one or more of adriamycin-resistant breast cancer, cisplatin-resistant lung cancer and cisplatin-resistant liver cancer cells, and the structure of the compound XH003 is as follows:
2. use according to claim 1, wherein the medicament comprises compound XH003, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable auxiliary agents.
3. The use according to claim 1, wherein the drug-resistant tumor is selected from the group consisting of doxorubicin-resistant breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110579672.2A CN113350356B (en) | 2021-05-26 | 2021-05-26 | 2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110579672.2A CN113350356B (en) | 2021-05-26 | 2021-05-26 | 2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113350356A CN113350356A (en) | 2021-09-07 |
| CN113350356B true CN113350356B (en) | 2022-12-27 |
Family
ID=77527809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110579672.2A Active CN113350356B (en) | 2021-05-26 | 2021-05-26 | 2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113350356B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180728A (en) * | 1989-09-25 | 1993-01-19 | Fujisawa Pharmaceutical Company, Ltd. | Pyrimidoindole derivatives and processes for preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100902340B1 (en) * | 2007-08-02 | 2009-06-12 | 한국생명공학연구원 | An agent for differentiating hematopoietic stem cell into natural killer cell comprising yc-1 or il-21 and a method of differentiating hematopoietic stem cell into natural killer cell using thereof |
| CN103710304B (en) * | 2012-09-29 | 2018-11-02 | 北京东方百奥医药开发有限公司 | Fat stem cell is induced to differentiate into the method and purposes of natural killer cells |
| EP3755355A4 (en) * | 2018-02-20 | 2022-01-05 | Universite De Montreal | Expansion of nk and dc cells in vivo mediating immune response |
| CN110156792A (en) * | 2019-06-28 | 2019-08-23 | 广州暨南生物医药研究开发基地有限公司 | A kind of pyrimido benzazolyl compounds and its preparation method and application |
-
2021
- 2021-05-26 CN CN202110579672.2A patent/CN113350356B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180728A (en) * | 1989-09-25 | 1993-01-19 | Fujisawa Pharmaceutical Company, Ltd. | Pyrimidoindole derivatives and processes for preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113350356A (en) | 2021-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101834366B1 (en) | Pharmaceutical composition for prevention or treatment of breast cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof | |
| CA2793526C (en) | Naphthofuran compounds and compositions for targeting cancer stem cells | |
| AU2011227023B2 (en) | Novel methods for targeting cancer stem cells | |
| DK3108750T3 (en) | NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS | |
| DK2615092T3 (en) | Heterocyclic AMINOBERBAMIN DERIVATIVES, PREPARATION METHOD AND USE THEREOF | |
| WO2016028225A1 (en) | Platinum complexes as anticancer agents | |
| CN101624376B (en) | Substituted hydrazide compound and application thereof | |
| EP2906564A1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
| AU2015218436A1 (en) | Novel Methods For Targeting Cancer Stem Cells | |
| CN113350356B (en) | 2,4, 7-trisubstituted pyrimidoindole compound with anti-tumor and drug-resistant effects | |
| CN101314584A (en) | HGF/c-Met signalling channel restrainer, preparation method and application thereof | |
| JP5701387B2 (en) | Dicarboximide derivative of berbamine, its preparation method and use | |
| CN116478175A (en) | Camptothecin-7-ethylamine derivative and preparation method and application thereof | |
| KR101039750B1 (en) | Novel coumarin based compound or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for inhibition of multidrug resistance containing the same as an active ingredient | |
| CN108707145B (en) | Quinoline compound containing five-membered heterocyclic structure and preparation and application thereof | |
| CN112851679B (en) | 2, 4, 7-trisubstituted pyrimidoindole compound with antitumor effect | |
| WO2016127949A1 (en) | Pyrimidine derivative as inhibitor for t790 mutation | |
| CN112851678B (en) | 2, 4, 7-trisubstituted pyrimidoindole compound with anti-tumor metastasis effect | |
| CN113880897B (en) | Flavonoid glycoside-organic amine tyrosine kinase inhibitor double salt compound and preparation method and application thereof | |
| CN112694507B (en) | Tetrahydro anthraquinone glycoside compound and application thereof in preparation of antitumor drugs | |
| CN108904503B (en) | Application of 6-chloro-5-nitro-2, 4-diaminopyrimidine in medicine for treating chronic granulocytic leukemia | |
| WO2016206138A1 (en) | Histone deacetylase inhibitor and preparation method and use thereof | |
| CN117229264A (en) | Aryl Schiff base compound containing 2-aminopyrimidine structure and application thereof | |
| WO2023274203A1 (en) | Nitrogen-containing polycyclic aromatic compound, preparation method therefor, and application thereof | |
| CN109453170A (en) | NF- kB inhibitor is preparing the application in anti-lung-cancer medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |